StudyFinder
Electronic Platform for Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long‐Acting Growth Hormone Therapy (LAuGH TRACK UMN)
Recruiting
The purpose of the study is to compare quality of life (QOL), adherence, insulin resistance, body composition and efficacy of LAGH to DGH in children with GHD.
Male or Female
Up to 18 years old
Inclusion Criteria:
• girls ages 2-11 years
• boys ages 2-13 years
• established diagnosis of pediatric growth hormone deficiency (GHD).
• For this study, GHD is defined as peak growth hormone response to clonidine/arginine stimulation testing of <10 ng/mL Either treatment-naive or currently treated with a daily growth hormone as approved by health insurance.
Exclusion Criteria:
• any medical condition which, in the opinion of the Investigator, can be an independent cause of short stature and/or limit the response to exogenous growth factor treatment
• current treatment with long-acting growth hormone
• currently pregnant or breastfeeding
Drug: Long-Acting Growth Hormone (LAGH)
Children's Health, Diabetes & Endocrine
Growth Hormone Deficiency
Brad Miller - mille685@umn.edu
Brad Miller, MD, PhD
STUDY00011784
See this study on ClinicalTrials.gov